Rossari Biotech Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tx54i9x53lx9yb56gnicm843.pdf

Key Takeaways


The Ethoxylation Ramp & the EO Constraint

Menezes: "Availability of Ethylene Oxide continues to be a near-term constraint. However, we are managing supplies prudently and are encouraged by indications that the situation should ease during the course of this calendar year."

KSA Greenfield: Rationale, Timing & Open Questions


B2C: The Drag That Could Flip

Sablok: "We are re-looking at that business all over again to reduce losses. And on a longer-term basis, also, we are assessing this piece of business of ours, and maybe in the next few quarters we may take some decisions on how we really plan to or what we plan to do with this B2C vertical."

Segment & Export Performance

SegmentTrendCommentary
HPPC▲ 11% YoYStable demand amid a muted domestic environment; Europe export sentiment soft but compensated by MENA, Middle East and Turkey.
Textile Specialty Chemicals▲ 18% YoYExport-driven growth from new customers in Turkey, Uzbekistan, Morocco, Philippines, Indonesia. Domestic soft as large end-customers like Welspun and Indo Count were hit by tariffs, though Surat and Ludhiana saw some demand recovery.
Animal Health & Nutrition▲ 39% YoYStrong quarter with improved traction across key end-user markets. Export initiative gaining ground with new country additions: Nepal, Bangladesh, Egypt, Nigeria, Thailand, and select South American markets. Second half is seasonally better.
Institutional & B2C▼ SubduedLosses moderating but performance still weak; active reassessment underway.

New Product Pipeline & R&D

Chari: "In fact, today, we have news that the best personal care company in the world has approved our bio-surfactants. 2 big multinationals of..."

Capex Cycle: Heavy Lifting Done, Optimization Ahead


Guidance & Commitments

CommitmentSpecificsTimeline
Ethoxylation capacityBalance second phase onstream; full utilization ~90% targetedQ4 FY26 for phase 2; end of FY27 for optimal utilization
Ethylene Oxide supplySituation expected to easeDuring calendar 2026
Margin range12-13% EBITDA, barring B2C actionBalance of FY26 and through next year until EO eases by Q3
B2C vertical decisionReassessment may lead to a decision on the vertical's futureNext few quarters
Thailand formulation facilitySmall facility upstream for textile, later AHN and HPPCEnd of Q4 FY26 or early Q1 FY27
Bangladesh AHN plantNew trace mineral and vitamin premix plant ready to startCurrent quarter (Q4 FY26)
KSA project capex detailDetailed capex quantification after assessment and evaluationNo date; formal Board approval for capex amount to follow
Non-EO capex (Unitop, Tristar, Rossari)Phased product-development capexQ3 and Q4 of next year (FY27)

Key Metrics

MetricQ3 FY26
Consolidated revenue₹581.7 cr, +13% YoY
Consolidated EBITDA₹68.9 cr, margin 11.8%
Core B2B EBITDA margin~14%, marginally lower than normalized band of 15%-16%
PAT~₹30 cr per quarter, broadly flat over several quarters (per an analyst's math)
ROCEsub-15%, close to 13% (per an analyst's math)
HPPC segment growth+11% YoY
Textile Specialty Chemicals segment growth+18% YoY
Animal Health and Nutrition segment growth+39% YoY
Export contribution33% of total turnover, 9M FY26 exports +26% YoY
Domestic growth (9M FY26)+10% YoY
Volume growth (consolidated YoY)~10%-12%, entire growth attributed to volume
New product sales share20%-plus of total sales
Unitop new Ethoxylation facility utilization10%-15% currently, expected to reach up to 90% by end of FY27
Total capex capitalized by end of FY26~₹200 cr across the group
Expected proceeds from sale of part of consumer businesses~₹150 cr